Predictive Technology Group, Inc.’s (PRED) Subsidiary Predictive Therapeutics Receives Notice of Allowance from the United States Patent and Trademark Office on Spine Deformity Diagnostic and Bio-Implant

Notice of Allowance Positively impacts Company’s Pipeline of Diagnostic Tests and Companion Treatment Technologies

Salt Lake City, UT — (March 21, 2016) – Predictive Technology Group, Inc. (OTCPINK:PRED), a life sciences technology holding company, announced its subsidiary Predictive Therapeutics received a ‘Notice of Allowance’ from the United States Patent and Trademark Office.  

Mike Schramm, Predictive Therapeutics’ Director of Intellectual Property, said, “We are pleased that the USPTO examiner agreed with the Patent Trial and Appeal Board and issued a ‘Notice of Allowance’ for all twenty pending claims of the ‘105 application. The claims of the ‘105 application build on previously issued US patents 8,123,787 and 8,641,738 to which ‘105 claims priority and further bolster PRED’s Intellectual Property position.”

Bradley Robinson, PRED’s CEO added, “PRED is excited to move forward with its spinal deformity tests and begin development work on companion therapeutics. This allowance is confirmation of our intellectual property strategy relating to the diagnostic tests and companion therapeutic candidates in our R&D pipeline. We are especially pleased to move our spine diagnostics and related therapeutics one step closer to providing surgeons better insights into the exact cause of their patients’ spine issues and ability to determine the best course of care for patients.”

PRED’s subsidiary Predictive Therapeutics strives to provide its surgeon customers with the highest quality predictive diagnostics and treatment solutions that can ultimately benefit their patients.

About Predictive Technology Group, Inc.

 Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of severe and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to prevent effectively and treat diseases.

For further information contact  Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090,, and/or

 Forward-Looking Statements

 To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.